Compugen (CGEN) Non Operating Income (2009 - 2026)
Compugen (CGEN) posted quarterly Non Operating Income of $1.4 million for Q1 2026, up 8.67% year-over-year from $1.2 million in Q1 2025, and up 68.7% on a QoQ basis from $802000.0 in Q4 2025.
Compugen (CGEN) Non Operating Income (2009 - 2026) Analysis & Trends
Compugen has reported Non Operating Income for 18 years, with the latest figure at $1.4 million in Q1 2026.
- Non Operating Income for Q1 2026 came in at $1.4 million, up 8.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (down 19.62% YoY), and the FY2025 annual result was $4.1 million, down 21.44% from the prior year.
- Non Operating Income grew to $1.4 million in Q1 2026, from $802000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.4 million in Q4 2024 and troughed at $286000.0 in Q1 2022.
- A 5-year average of $914823.5 and a median of $889000.0 in 2023 frame the typical range for Non Operating Income.
- The widest annual swing landed in 2022, when Non Operating Income surged 266.67%; it then sank 41.46% in 2025.
- A 5-year view of Non Operating Income shows it stood at $495000.0 in 2022, then soared by 48.48% to $735000.0 in 2023, then surged by 86.39% to $1.4 million in 2024, then sank by 41.46% to $802000.0 in 2025, then soared by 68.7% to $1.4 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $1.4 million in Q1 2026, $802000.0 in Q4 2025, and $954000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Compugen | 227.88 Mn | 136.13 Mn | 352,000.00 | 1.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.35 Mn |
| Dec 31, 2025 | 802,000.00 |
| Sep 30, 2025 | 954,000.00 |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 735,000.00 |
| Sep 30, 2023 | 776,000.00 |
| Jun 30, 2023 | 889,000.00 |
| Mar 31, 2023 | 808,000.00 |
| Dec 31, 2022 | 495,000.00 |
| Sep 30, 2022 | 464,000.00 |
| Jun 30, 2022 | 493,000.00 |
| Mar 31, 2022 | 286,000.00 |
| Dec 31, 2021 | 135,000.00 |
| Sep 30, 2021 | 177,000.00 |
| Jun 30, 2021 | 200,000.00 |